{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:47:45Z","timestamp":1769856465102,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.biopha.2018.07.030","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T01:37:56Z","timestamp":1531359476000},"page":"831-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Albizia zygia root extract exhibits antipsychotic-like properties in murine models of schizophrenia"],"prefix":"10.1016","volume":"106","author":[{"given":"Victor Wumbor-Apin","family":"Kumbol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-4231","authenticated-orcid":false,"given":"Wonder Kofi Mensah","family":"Abotsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-7121","authenticated-orcid":false,"given":"Edmund","family":"Ekuadzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Woode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.07.030_bib0005","series-title":"Schizophrenia","author":"WHO","year":"2016"},{"key":"10.1016\/j.biopha.2018.07.030_bib0010","series-title":"Schizophrenia Fact Sheet","author":"WHO","year":"2016"},{"key":"10.1016\/j.biopha.2018.07.030_bib0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3649","article-title":"Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap","volume":"11","author":"Pratt","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2018.07.030_bib0020","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2018.07.030_bib0025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/ps.2008.59.5.500","article-title":"Special section on implications of CATIE: what CATIE found: results from the schizophrenia trial","volume":"59","author":"Swartz","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.biopha.2018.07.030_bib0030","series-title":"Ressources v\u00e9g\u00e9tales de l\u2019Afrique tropicale 7(1)","first-page":"67","article-title":"Albizia zygia (DC.) J.F.Macbr.","author":"Apetorgbor","year":"2008"},{"key":"10.1016\/j.biopha.2018.07.030_bib0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jep.2006.10.036","article-title":"In vitro antiprotozoal activities and cytotoxicity of some selected Cameroonian medicinal plants","volume":"111","author":"Ndjakou Lenta","year":"2007","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2018.07.030_bib0040","series-title":"Plantes m\u00e9dicinales de la C\u00f4te d\u2019Ivoire. Travaux et Documents de l\u2019ORSTOM No. 32","author":"Bouquet","year":"1974"},{"key":"10.1016\/j.biopha.2018.07.030_bib0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.phytol.2016.09.010","article-title":"Two new triterpenoid saponins from the roots of Albizia zygia (DC.) JF Macbr","volume":"18","author":"Not\u00e9","year":"2016","journal-title":"Phytochem. Lett."},{"key":"10.1016\/j.biopha.2018.07.030_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jep.2017.02.007","article-title":"Albizia zygia (DC.) J.F. Macbr. (Leguminosae-Mimosoideae) root extract exhibits anti-nociceptive and antipyretic activities in murine models","volume":"199","author":"Abotsi","year":"2017","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2018.07.030_bib0055","first-page":"199","article-title":"Albizia zygia (DC.) Macbr. Hydroethanol root extract exerts anti-oedemic and in vivo antioxidant activities in animal models","volume":"7","author":"Lamptey","year":"2017","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.biopha.2018.07.030_bib0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","volume":"28","author":"Frohlich","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2018.07.030_bib0065","series-title":"Trease and Evans\u2019 Pharmacognosy","author":"Evans","year":"2002"},{"key":"10.1016\/j.biopha.2018.07.030_bib0070","series-title":"Medicinal Plants and Traditional Medicine in Africa","author":"Soforowa","year":"1993"},{"issue":"1","key":"10.1016\/j.biopha.2018.07.030_bib0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-008-1103-1","article-title":"Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice","volume":"198","author":"Chan","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2018.07.030_bib0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbr.2010.08.001","article-title":"Effect of\u2019 chronic\u2019 versus\u2019 acute\u2019 ketamine administration and its\u2019 withdrawal\u2019 effect on behavioural alterations in mice: implications for experimental psychosis","volume":"216","author":"Chatterjee","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2018.07.030_bib0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.physbeh.2013.03.008","article-title":"Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis","volume":"114","author":"Dixit","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2018.07.030_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2016.00464","article-title":"Mitragyna speciosa leaf extract exhibits antipsychotic-like effect with the potential to alleviate positive and negative symptoms of psychosis in mice","volume":"7","author":"Vijeepallam","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2018.07.030_bib0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2018.07.030_bib0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/FBP.0000000000000267","article-title":"LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition","volume":"28","author":"Betti","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.biopha.2018.07.030_bib0105","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3109\/13880209.2014.976350","article-title":"Antipsychotic activity of standardized Bacopa extract against ketamine-induced experimental psychosis in mice: evidence for the involvement of dopaminergic, serotonergic, and cholinergic systems","volume":"53","author":"Chatterjee","year":"2015","journal-title":"Pharm. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.030_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00634146","article-title":"Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum","volume":"50","author":"Protais","year":"1976","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.biopha.2018.07.030_bib0115","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.07.030_bib0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1515\/revneuro-2013-0011","article-title":"Does the dopamine hypothesis explain schizophrenia?","volume":"24","author":"Lau","year":"2013","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.biopha.2018.07.030_bib0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Pratt","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2018.07.030_bib0130","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","volume":"35","author":"Gobira","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.biopha.2018.07.030_bib0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2018.07.030_bib0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(97)01390-5","article-title":"Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia","volume":"787","author":"Duncan","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2018.07.030_bib0145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1034\/j.1399-6576.2003.00040.x","article-title":"Inhibitory effect of propofol on ketamine-induced c-Fos expression in the rat posterior cingulate and retrosplenial cortices is mediated by GABAA receptor activation","volume":"47","author":"Nakao","year":"2003","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.biopha.2018.07.030_bib0150","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2018.07.030_bib0155","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/jpet.110.166710","article-title":"Behavioral indices in antipsychotic drug discovery","volume":"333","author":"Porsolt","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2018.07.030_bib0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001756-200101220-00010","article-title":"Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment","volume":"12","author":"Qiao","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.biopha.2018.07.030_bib0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-9964(02)00168-8","article-title":"Visual object processing in schizophrenia: evidence for an associative agnosic deficit","volume":"59","author":"Gabrovska","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.biopha.2018.07.030_bib0170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","article-title":"Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia","volume":"122","author":"Young","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2018.07.030_bib0175","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00213-011-2536-5","article-title":"Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models","volume":"220","author":"Lyon","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2018.07.030_bib0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","article-title":"Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat","volume":"184","author":"Grayson","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2018.07.030_bib0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"Shin","year":"2012","journal-title":"J. Clin. Neurol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218326283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218326283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:32:30Z","timestamp":1750879950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218326283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":37,"alternative-id":["S0753332218326283"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.030","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albizia zygia root extract exhibits antipsychotic-like properties in murine models of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}